Latest Breaking News On - D228 - Page 1 : comparemela.com

BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

United statesStephens yoderSociety for immunotherapy of cancerPieris pharmaceuticalsCompany quarterly reports on formCompany annual report on formExchange commissionPieris pharmaceuticals inc viewSecurities exchangePieris pharmaceuticals incAnnual meetingLooking statementsSecurities actSecurities exchange actAnnual reportQuarterly reports